Argenx Presents New Vyvgart Data at AANEM and MGFA Congresses
The immunology group listed on Euronext and Nasdaq announced the presentation of clinical, long-term and real-world data on Vyvgart and candidates from its portfolio at the AANEM and MGFA scientific session congresses, held in Orlando from September 29 to October 2, 2026.
These presentations cover myasthenia gravis (MG), chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) as well as the molecules empasiprubart and adimanebart.
Argenx indicated that the data presented concern the expansion of Vyvgart use in myasthenia gravis, including in patient populations historically absent from clinical trials.
According to Luc Truyen, medical director of the group, the ambition is to benefit the greatest number of patients while simplifying treatment decisions for clinicians managing MG and CIDP, with "a clear treatment choice regardless of the patient's antibody status".
The company also reported data supporting the interest of earlier treatment in MG and CIDP.
Empasiprubart and Adimanebart for Other Mechanisms
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
Beyond Vyvgart, Argenx presented results concerning empasiprubart and adimanebart, two molecules that target distinct mechanisms in neuromuscular diseases described as still under-treated.
The group specified that the results of a phase 2 study of empasiprubart in multifocal motor neuropathy (MMN) support its potential as selective complement therapy of a biological pathway.
The presentations also include long-term data and a phase 4 study regarding direct transition from IVIg in CIDP.
SectorPharmacie et biotechnologies›Biotechnologies
Free · every morning · before 9am
Never miss a move on your stocks
The trend behind the prices · Euronext
✓ You're in! Check your spam folder.
An error occurred.
Context
Period
Period: 9M 2026
Key reported figures
Revenue: 4 605 millions de dollars
Quarterly revenue: 4 605 millions de dollars
Revenue growth: 57,4 %
Net income: 1 344 millions de dollars
Guidance from the release
argenx remains on track to achieve its 'Vision 2030' anchored in the ambition to treat 50,000 patients globally
Risks mentioned
The risk that early stage clinical trials may not be predictive of results in later stage or large scale clinical trials
Demand and commercialization risks for argenx's products and product candidates, including new indications
Regulatory and pricing uncertainties for argenx's products and product candidates if approved
Opportunities identified
Vision 2030 targets: treat 50,000 patients globally, secure 10 labeled indications, and progress five pipeline candidates
Multiple label and indication expansions for VYVGART being pursued across additional autoimmune diseases
Next-generation FcRn molecules (ARGX-213 Phase 3-ready, ARGX-124 in Phase 1) advancing through development
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
